OP0183 DO CARTILAGE LAMINAR COMPOSITIONAL CHANGES AS ASSESSED BY T2 RELAXOMETRY PREDICT INCIDENT AND WORSENING OF STRUCTURAL MORPHOLOGIC DAMAGE IN THE SAME PLATE 3 YEARS LATER?

Abstract

Background:To address the question whether laminar changes in knee cartilage T2 are relevant for prediction of lesion onset or progression in the same articular plate we included two different samples from the Osteoarthritis Initiative (OAI) study without radiographic osteoarthritis (ROA), i.e. so-called “healthy controls” with no ROA in either knee and being free of risk factors, and those with K-L 0 in one knee and ROA in the contralateral knee. Given the concept of the osteochondral unit, we hypothesize that superficial T2 is elevated in cartilage plates with subsequent surface damage development or worsening and deep layer T2 is elevated for those with subsequent bone marrow lesion (BML) development or worsening.Objectives:To analyze whether knees with subsequent morphologic cartilage and BML development or worsening exhibit elevated cartilage T2 compared to those that do not develop such structural damage in the same plate 3 years later.Methods:We included 63 knees from the OAI without ROA (K-L 0), but with definite ROA (K-L ≥2) in the contralateral knee, and 78 participants from the OAI healthy reference cohort.Cartilage integrity or damage and subchondral bone marrow lesions (BMLs) were assessed for year 1 (i.e. baseline (BL) in this analysis) and year 4 (Y4) in chronological order using the semi-quantitative MOAKS scoring system.BL deep and superficial layer cartilage T2 was computed from sagittal multi-echo spin echo MR images. Because cartilage T2 is known to display spatial variation with tissue depth, the segmented cartilages were computationally divided into superficial and deep 50%, based on the distance between the segmented cartilage surface and bone interface. Statistical analyses were performed for the femoro-tibial (FT) joint on a plate level, i.e. medial femur (MF), medial tibia (MT), lateral femur (LF) and lateral tibia (LT), using UNIANOVA with adjustment for age, body mass index, sex, and sample.Results:141 participants were included. Of these 79 (56%) were women, had a mean age of 59.4 ± 9.1 years and a mean body mass index of 25.8 ± 4.1 m/kg2.52 (37%) had prevalent cartilage lesions in the medial FT joint and 67 (48%) in the lateral FT joint. For BMLs these numbers were 15 (11%) medially and 14 (10%) laterally. Worsening of FT cartilage lesions from BL to Y4 were seen in 10 (7%) medially and 21 (15%) in the lateral FT compartment. Incident FT cartilage lesions were seen in 11 (11.5%) medially and 8 knees laterally. No worsening BMLs were seen medially and 2 knees showed worsening BMLs laterally. 10 (7%) knees showed incident BMLs medially and 8 (6%) knees in the lateral FT compartment.Deep layer T2 showed prolongation in the LT in knees with incident LT cartilage lesions (n=8, 34.5 vs. 32.7 ms, p=0.02) and for MF in knees with MF cartilage lesion worsening (n=9, 47.6 vs. 41.4 ms, p=0.01) and MF BML incidence (n=6, 45.4 vs.41.6 ms, p=0.000). Superficial T2 showed prolongation in the MT only in those knees with MT cartilage lesion worsening (n=2, 47.3 vs. 43.4 ms, p=0.03). No additional associations were seen for the superficial layer.Conclusion:For knees without ROA, BL deep layer T2 prolongation was seen for those who developed incident cartilage damage in the LT, and those with worsening cartilage damage and incident BMLs in the MF, respectively. Superficial T2 showed prolongation only in the MT for those with MT cartilage lesion worsening.In summary and contrary to our hypothesis the deep cartilage layer seems to be more relevant for cartilage damage development or worsening in the same FT plate than the superficial layer.Acknowledgment:German Bundesministerium für Bildung und Forschung (BMBF – 01EC1408D -OVERLOAD-PREVOP)Disclosure of Interests:Frank Roemer: None declared, Felix Eckstein Grant/research support from: Merck, Orthotrphix, Servier, Galapagos, Kolon Tissuegene, Samumed, Novartis, Consultant of: Merck, Bioclinica, Servier, Samumed, Roche, Kolon Tissuegene, Galapagos and Novartis, Employee of: co-owner and employment with Chondrometrics, Georg Duda: None declared, Susanne Maschek Shareholder of: Stock/stock options at Condrometrics GmbH, Employee of: Employment at Condrometrics GmbH, Ali Guermazi Consultant of: AventisGalapagos, Pfizer, Roche, AstraZeneca, Merck Serono, and TissuGene, Wolfgang Wirth: None declared